Literature DB >> 15140180

Clearing amyloid through the blood-brain barrier.

Berislav V Zlokovic1.   

Abstract

According to the amyloid hypothesis, accumulation of amyloid beta-peptide (A beta) in the brain is the primary pathogenic event in Alzheimer's disease (AD). Recent evidence indicates that A beta within the intravascular space is linked to A beta deposited in the brain suggesting that transport of A beta between the brain, blood and cerebrospinal fluid, and across the blood-brain barrier, regulates brain A beta. Thus, understanding A beta exchanges between brain and blood, and vice versa, and developing transport-based systemic A beta-lowering strategies may provide new important insights into pathogenesis and therapeutic control of AD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15140180     DOI: 10.1111/j.1471-4159.2004.02385.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  102 in total

1.  The expression of LDL receptor in vessels with blood-brain barrier impairment in a stroke-prone hypertensive model.

Authors:  Masaki Ueno; Bin Wu; Toshitaka Nakagawa; Yukiko Nagai; Masayuki Onodera; Cheng-Long Huang; Takashi Kusaka; Kenji Kanenishi; Haruhiko Sakamoto
Journal:  Histochem Cell Biol       Date:  2010-05-11       Impact factor: 4.304

Review 2.  Current therapeutic targets for the treatment of Alzheimer's disease.

Authors:  Joshua D Grill; Jeffrey L Cummings
Journal:  Expert Rev Neurother       Date:  2010-05       Impact factor: 4.618

3.  Blood-brain barrier and Alzheimer's.

Authors:  Jim Sondecker; Michael Smith; Dave Robinson
Journal:  Psychiatry (Edgmont)       Date:  2005-06

Review 4.  Amyloid-modifying therapies for Alzheimer's disease: therapeutic progress and its implications.

Authors:  Meaghan C Creed; Norton W Milgram
Journal:  Age (Dordr)       Date:  2010-04-20

5.  Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease.

Authors:  Martin J Sadowski; Joanna Pankiewicz; Henrieta Scholtzova; Pankaj D Mehta; Frances Prelli; David Quartermain; Thomas Wisniewski
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-20       Impact factor: 11.205

6.  Liver production of sulfamidase reverses peripheral and ameliorates CNS pathology in mucopolysaccharidosis IIIA mice.

Authors:  Albert Ruzo; Miquel Garcia; Albert Ribera; Pilar Villacampa; Virginia Haurigot; Sara Marcó; Eduard Ayuso; Xavier M Anguela; Carles Roca; Judith Agudo; David Ramos; Jesús Ruberte; Fatima Bosch
Journal:  Mol Ther       Date:  2011-10-18       Impact factor: 11.454

7.  The choroid plexus removes beta-amyloid from brain cerebrospinal fluid.

Authors:  Janelle S Crossgrove; G Jane Li; Wei Zheng
Journal:  Exp Biol Med (Maywood)       Date:  2005-11

8.  Mapping the interactions between the Alzheimer's Aβ-peptide and human serum albumin beyond domain resolution.

Authors:  Moustafa Algamal; Julijana Milojevic; Naeimeh Jafari; William Zhang; Giuseppe Melacini
Journal:  Biophys J       Date:  2013-10-01       Impact factor: 4.033

9.  Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system.

Authors:  Robert D Bell; Abhay P Sagare; Alan E Friedman; Gurrinder S Bedi; David M Holtzman; Rashid Deane; Berislav V Zlokovic
Journal:  J Cereb Blood Flow Metab       Date:  2006-11-01       Impact factor: 6.200

10.  Neurogenic effects of β-amyloid in the choroid plexus epithelial cells in Alzheimer's disease.

Authors:  Marta Bolos; Carlos Spuch; Lara Ordoñez-Gutierrez; Francisco Wandosell; Isidro Ferrer; Eva Carro
Journal:  Cell Mol Life Sci       Date:  2013-03-03       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.